[Federal Register Volume 62, Number 205 (Thursday, October 23, 1997)]
[Rules and Regulations]
[Pages 55158-55159]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-28017]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 510 and 520
Animal Drugs, Feeds, and Related Products; Selegiline
Hydrochloride Tablets; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a
[[Page 55159]]
final rule that appeared in the Federal Register of June 27, 1997 (62
FR 34631). The document amended the animal drug regulations to reflect
approval of a new animal drug application (NADA) filed by Deprenyl
Animal Health, Inc. The NADA provides for oral use of selegiline
hydrochloride tables for dogs for the control of clinical signs
associated with uncomplicated pituitary-dependent hyperadrenocorticism.
The approved use in dogs was inadvertently omitted from the document.
This document corrects that error.
EFFECTIVE DATE: June 27, 1997.
FOR FURTHER INFORMATION CONTACT: David L. Gordon, Center for Veterinary
Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301-594-1739.
In FR Doc. 97-16791, appearing on page 34631 in the Federal
Register of Friday, June 27, 1997, the following corrections are made:
1. On page 34631, in the first column, in the heading ``Tablet'' is
corrected to read ``Tablets''.
Sec. 520.2098 [Corrected]
2. On page 34632, in the first column, in Sec. 520.2098 Selegiline
hydrochloride tablets, in paragraph (d), the heading ``(d) Conditions
of use--'' is corrected to read ``(d) Conditions of use--Dogs--''; and
in paragraph (d)(2), in the 4th line, ``hyperadrenocorticism.'' is
corrected to read ``hyperadrenocorticism in dogs.''
Dated: September 8, 1997.
Robert C. Livingston,
Director, Office of New Animal Drug Evaluation, Center for Veterinary
Medicine.
[FR Doc. 97-28017 Filed 10-22-97; 8:45 am]
BILLING CODE 4160-01-F
